Patents, Innovation and Access to New Pharmaceuticals
AbstractThis paper considers the role of intellectual property rights in the development of and access to new pharmaceuticals. A number of studies have found patents are significantly more important to pharmaceutical firms in appropriating the benefits from innovation compared to other high tech industries. The reason for this is because the costs of drug innovation are very high while the costs of imitation are relatively low. Hence the industry is subject to significant free rider problems. The paper discusses the economics of the innovative process and considers how patent policies have evolved in response to these characteristics in several developed countries with research intensive drug firms. One area currently receiving policy attention is the effect of patents on the development of and access to new medicines in developing countries. The final section of the paper focuses on this issue and discusses the need for an orphan drug type program to stimulate more R&D on diseases specific to third world countries.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by Duke University, Department of Economics in its series Working Papers with number 02-28.
Date of creation: 2002
Date of revision:
Contact details of provider:
Postal: Department of Economics Duke University 213 Social Sciences Building Box 90097 Durham, NC 27708-0097
Phone: (919) 660-1800
Fax: (919) 684-8974
Web page: http://econ.duke.edu/
This paper has been announced in the following NEP Reports:
- NEP-ALL-2003-02-18 (All new papers)
- NEP-COM-2003-02-18 (Industrial Competition)
- NEP-HEA-2003-02-18 (Health Economics)
- NEP-IND-2003-02-20 (Industrial Organization)
You can help add them by filling out this form.
CitEc Project, subscribe to its RSS feed for this item.
- Kyle, Margaret K & McGahan, Anita M, 2011.
"Investments in Pharmaceuticals Before and After TRIPS,"
CEPR Discussion Papers
8371, C.E.P.R. Discussion Papers.
- Margaret K. Kyle & Anita M. McGahan, 2012. "Investments in Pharmaceuticals Before and After TRIPS," The Review of Economics and Statistics, MIT Press, vol. 94(4), pages 1157-1172, November.
- Margaret Kyle & Anita McGahan, 2009. "Investments in Pharmaceuticals Before and After TRIPS," NBER Working Papers 15468, National Bureau of Economic Research, Inc.
- Michel Dumont & Peter Willemé, 2013. "Working Paper 02-13 - Machines that go ‘ping’: medical technology and health expenditures in OECD countries," Working Papers 1302, Federal Planning Bureau, Belgium.
- Luiz Flavio Andrade, 2012. "Entry Time Effects and Follow-on Drugs Competition," Working Papers DT49, IRDES institut for research and information in health economics, revised Jun 2012.
- Alka Chadha & Åke Blomqvist, 2005. "Patent Races, “Me-Too” Drugs, and Generics: A Developing-World Perspective," Departmental Working Papers wp0513, National University of Singapore, Department of Economics.
- Langinier, Corinne, 2004.
"Are Patents Strategic Barriers to Entry?,"
Staff General Research Papers
11482, Iowa State University, Department of Economics.
- Ants Kukrus & Raul Kartus, 2005. "Patent Protection of Pharmaceutical Products in the Globalising World Economy," Working Papers 136, Tallinn School of Economics and Business Administration, Tallinn University of Technology.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Department of Economics Webmaster).
If references are entirely missing, you can add them using this form.